Literature DB >> 32382155

Antihypertensive activity of a new c-Jun N-terminal kinase inhibitor in spontaneously hypertensive rats.

Mark B Plotnikov1,2, Oleg I Aliev3, Aleksandr Y Shamanaev3, Anastasia V Sidekhmenova3, Anna M Anishchenko3,4, Tatiana I Fomina3, Victoria S Rydchenko5, Andrei I Khlebnikov6,7, Yana J Anfinogenova6,8, Igor A Schepetkin6,9, Dmitriy N Atochin6,10.   

Abstract

c-Jun N-terminal kinases (JNKs) are involved in the myocardial and aortic remodeling, increased arterial tone, and arterial blood pressure elevation associated with hypertension. The aim of the present study was to investigate the antihypertensive effect of a new JNK inhibitor, 1H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt (IQ-1S), on spontaneously hypertensive rats (SHRs). Experiments were performed using normotensive Wistar-Kyoto (WKY) rats and SHRs. Experimental groups of SHRs received IQ-1S intragastrically for 6 weeks in daily doses of 5 and 50 mg/kg; experimental groups of WKY rats received 50 mg/kg IQ-1S according to the same regimen. The IQ-1S administration regimen induced decreases in systolic blood pressure, mean arterial blood pressure, total peripheral resistance, blood viscosity, hematocrit, myocardial cell cross-sectional area, and aortic wall thickness in SHRs vs untreated SHRs. There were no significant differences in systolic blood pressure values between the control and experimental groups of WKY rats during the treatment period. A concentration-dependent decrease in the tone of carotid arterial rings isolated from SHRs was observed after JNK inhibitor application in vitro. Application of the JNK inhibitor diminished endothelin-1 secretion by human umbilical vein endothelial cells in vitro. The main mechanisms of the antihypertensive effect of IQ-1S included the attenuation of blood viscosity due to decreased hematocrit, a vasodilatory effect on arterial smooth muscle cells, and a decrease in endothelin-1 production by endothelial cells.

Entities:  

Keywords:  1H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt; Antihypertensive activity; Endothelin-1 production by endothelial cells; Inhibition of myocardial and aorta remodeling; JNK inhibitor

Year:  2020        PMID: 32382155     DOI: 10.1038/s41440-020-0446-9

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  50 in total

Review 1.  New insights in the pharmacological therapy of arterial hypertension.

Authors:  Angel Cogolludo; Francisco Pérez-Vizcaíno; Juan Tamargo
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-09       Impact factor: 2.894

Review 2.  "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium.

Authors:  P H Sugden; A Clerk
Journal:  Circ Res       Date:  1998-08-24       Impact factor: 17.367

3.  Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy.

Authors:  T Yamazaki; I Komuro; S Kudoh; Y Zou; I Shiojima; Y Hiroi; T Mizuno; K Maemura; H Kurihara; R Aikawa; H Takano; Y Yazaki
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

4.  Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats.

Authors:  Y Izumi; S Kim; Y Zhan; M Namba; H Yasumoto; H Iwao
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

5.  Cardiac hypertrophy in the Prague-hypertensive rat is associated with enhanced JNK2 but not ERK tissue activity.

Authors:  V Vogel; D Bokemeyer; J Heller; H J Kramer
Journal:  Kidney Blood Press Res       Date:  2001       Impact factor: 2.687

6.  Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor-Binding Protein).

Authors:  Elena Tassi; En Yin Lai; Lingli Li; Glenn Solis; Yifan Chen; William E Kietzman; Patricio E Ray; Anna T Riegel; William J Welch; Christopher S Wilcox; Anton Wellstein
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

7.  Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy.

Authors:  G Choukroun; R Hajjar; J M Kyriakis; J V Bonventre; A Rosenzweig; T Force
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

8.  Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension.

Authors:  M Yano; S Kim; Y Izumi; S Yamanaka; H Iwao
Journal:  Circ Res       Date:  1998-10-05       Impact factor: 17.367

Review 9.  Role of hypertension in atherosclerosis and cardiovascular disease.

Authors:  W Hollander
Journal:  Am J Cardiol       Date:  1976-11-23       Impact factor: 2.778

Review 10.  The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters.

Authors:  Dario R Alessi; Jinwei Zhang; Arjun Khanna; Thomas Hochdörfer; Yuze Shang; Kristopher T Kahle
Journal:  Sci Signal       Date:  2014-07-15       Impact factor: 8.192

View more
  2 in total

Review 1.  Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.

Authors:  Igor A Schepetkin; Mark B Plotnikov; Andrei I Khlebnikov; Tatiana M Plotnikova; Mark T Quinn
Journal:  Biomolecules       Date:  2021-05-22

Review 2.  Alarmins and c-Jun N-Terminal Kinase (JNK) Signaling in Neuroinflammation.

Authors:  Nina D Anfinogenova; Mark T Quinn; Igor A Schepetkin; Dmitriy N Atochin
Journal:  Cells       Date:  2020-10-24       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.